Valuation: Black Diamond Therapeutics, Inc.

Market Cap 105M 92.73M 86.15M 79.23M 149M 10.21B 151M 1.03B 402M 4.98B 396M 387M 17.28B P/E 2026 *
-2.84x
P/E 2027 * -1.83x
Enterprise Value 105M 92.73M 86.15M 79.23M 149M 10.21B 151M 1.03B 402M 4.98B 396M 387M 17.28B EV / Sales 2026 *
19x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 16/09/2023
Chief Tech/Sci/R&D Officer 51 11/08/2021
Director of Finance/CFO 41 07/10/2024
Director TitleAgeSince
Director/Board Member 61 01/03/2017
Director/Board Member 47 01/12/2019
Director/Board Member 49 01/12/2018
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 105M
+1.23%+0.35%+51.62%+87.98% 55.92B
+1.51%+7.58%+63.77%+68.93% 56.67B
+0.25%+0.55%-19.67%-15.22% 23.28B
+0.72%-0.05%+3.84%+409.54% 23.28B
-0.36%+5.73%+30.99%-3.58% 20.54B
-0.81%+1.31%+26.02%-29.71% 17.78B
-1.44%+5.67%+32.54%+544.11% 15.9B
-2.54%-8.73%+164.11%+289.45% 14.64B
+1.22%-0.05%+22.58%+182.63% 13.99B
Average -0.02%+1.26%+41.76%+170.46% 26.89B
Weighted average by Cap. +0.47%+3.18%+43.25%+135.73%

Financials

2026 *2027 *
Net sales 5.56M 4.89M 4.54M 4.17M 7.83M 538M 7.97M 54.28M 21.17M 262M 20.86M 20.41M 910M -
Net income -40.47M -35.6M -33.07M -30.41M -57.04M -3.92B -58.06M -395M -154M -1.91B -152M -149M -6.63B -70.04M -61.6M -57.23M -52.64M -98.71M -6.78B -100M -684M -267M -3.31B -263M -257M -11.48B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.840USD
Average target price
9.857USD
Spread / Average Target
+435.71%

Quarterly revenue - Rate of surprise